Evidence map›Paper›PMID 37474735›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2023

Early biochemical and radiographic response after one cycle of [

Wojciech Cytawa, Robin Hendel, Bartłomiej Tomasik, Franz-Xaver Weinzierl, Thorsten Bley, Jacek Jassem, Andreas Schirbel, Andreas K Buck, Ralph A Bundschuh, Philipp E Hartrampf and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. FDG/PSMA discordance in [Frontiers in oncology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Wojciech CytawaDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Robin HendelDepartment of Radiology, University Hospital Würzburg, Würzburg, Germany.
Bartłomiej TomasikDepartment of Oncology and Radiotherapy, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Franz-Xaver WeinzierlDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Thorsten BleyDepartment of Radiology, University Hospital Würzburg, Würzburg, Germany.
Jacek JassemDepartment of Oncology and Radiotherapy, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Andreas SchirbelDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Andreas K BuckDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Ralph A BundschuhNuclear Medicine, Faculty of Medicine, University of Augsburg, Stenglinstr. 2, 86156, Augsburg, Germany.
Philipp E HartrampfDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Rudolf A WernerDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Constantin LapaNuclear Medicine, Faculty of Medicine, University of Augsburg, Stenglinstr. 2, 86156, Augsburg, Germany. constantin.lapa@uk-augsburg.de.ORCID 0000-0001-7536-2207
Universitätsklinikum Würzburg · DEGdańsk Medical University · PLUniversity of Augsburg · DE

Funding

Gdansk University 71-1212
6 · The paper itself

Abstract

purposeThe aim of this study was to investigate very early radiographic PSMA PET response after one cycle of [

methodsThis retrospective study enrolled 40 mCRPC patients who were treated with a median of 3 (2-9) [

resultsAfter one cycle of RLT, biochemical partial response (PR) was seen in 8/40 (20.0%), stable disease (SD) in 22/40 (55.0%), and progressive disease (PD) in 10/40 (25%) patients. In PSMA PET, very early molecular PR was observed in 12 (30.0%), SD in 19 (47.5%), and PD in 9 (22.5%) subjects. The PSA and TLP nadir were achieved after a median of 1 (1-5) and 2 (1-6) cycles, respectively. Nineteen (47.5%) patients showed overall biochemical PR, 11 (27.5%) had SD, and 10 (25%) experienced PD. In PSMA-directed PET, 4 patients experienced molecular complete response (CR), 24 (60.0%) had PR, 4 (10.0%) SD, and 8 (20.0%) PD. Early biochemical or radiographic response was not associated with longer overall survival (OS). Overall biochemical responders had a nearly significantly longer median OS (22.7 months) than non-responders (14.4 months, p = 0.08). Early PSA progression was associated with shorter OS (12.2 months), compared to biochemical SD/PR (18.7 months, p = 0.09).

conclusionIn this retrospective cohort, there was no association between early PSMA PET radiographic response and overall survival; hence, treatment should not be prematurely discontinued. In contrast, early PSA progression after one cycle of [

Indexed as

Prostatic Neoplasms, Castration-ResistantDipeptidesHeterocyclic Compounds, 1-RingHumansLutetiumMaleProstate-Specific AntigenRetrospective StudiesTreatment OutcomeUreaDipeptidesHeterocyclic Compounds, 1-RingLutetiumProstate-Specific AntigenPSMA I&TUrea[177Lu]Lu-PSMA I&TEarly response assessmentMetastatic castration-resistant prostate cancerRadioligand therapy

Identifiers

PMID37474735
PMCPMC10547638
OpenAlexW4384922400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.